200 related articles for article (PubMed ID: 24146342)
21. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.
Liu L; Xu HX; Wang WQ; Wu CT; Xiang JF; Liu C; Long J; Xu J; Fu de L; Ni QX; Houchen CW; Postier RG; Li M; Yu XJ
Oncotarget; 2016 Feb; 7(5):5943-56. PubMed ID: 26745601
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
23. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
24. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
25. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.
Zhang S; Wang YM; Sun CD; Lu Y; Wu LQ
World J Gastroenterol; 2008 Jun; 14(23):3750-3. PubMed ID: 18595144
[TBL] [Abstract][Full Text] [Related]
27. Hysteroscopy combined dilatation and curettage, serum CA125 and CA19-9 play an important role in preserving fertility or endocrine function for early-stage endometrial cancer patients.
Ni T; Liu Y; Huang Y; Sun X; Wang J; Wang YD
Eur J Gynaecol Oncol; 2017; 38(1):49-53. PubMed ID: 29767864
[TBL] [Abstract][Full Text] [Related]
28. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
29. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
30. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242.
Björkman K; Mustonen H; Kaprio T; Kekki H; Pettersson K; Haglund C; Böckelman C
Tumour Biol; 2021; 43(1):57-70. PubMed ID: 33935125
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
[TBL] [Abstract][Full Text] [Related]
33. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
34. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
[TBL] [Abstract][Full Text] [Related]
35. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
[TBL] [Abstract][Full Text] [Related]
36. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
37. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
38. Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas.
Sun LQ; Peng LS; Guo JF; Jiang F; Cui F; Huang HJ; Jin ZD
World J Gastroenterol; 2021 Feb; 27(6):501-512. PubMed ID: 33642824
[TBL] [Abstract][Full Text] [Related]
39. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
40. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
